Department of Hematology, Saint Antoine Hospital, Paris, France
Federico II University, Hematology Department, Naples, Italy.
Haematologica. 2019 Aug;104(8):1682-1688. doi: 10.3324/haematol.2018.198549. Epub 2019 Feb 7.
Fecal microbiota transplantation is an effective treatment in recurrent infection. Promising results to eradicate multidrug-resistant bacteria have also been reported with this procedure, but there are safety concerns in immunocompromised patients. We report results in ten adult patients colonized with multidrug-resistant bacteria, undergoing fecal microbiota transplantation before (n=4) or after (n=6) allogeneic hematopoietic stem cell transplantation for hematologic malignancies. were obtained from healthy related or unrelated donors. Fecal material was delivered either by enema or nasogastric tube. Patients were colonized or had infections from either carbapenemase-producing bacteria (n=8) or vancomycin-resistant enterococci (n=2). Median age at fecal microbiota transplantation was 48 (range, 16-64) years. Three patients needed a second transplant from the same donor due to initial failure of the procedure. With a median follow up of 13 (range, 4-40) months, decolonization was achieved in seven of ten patients. In all patients, fecal micro-biota transplantation was safe: one patient presented with constipation during the first five days after FMT and two patients had grade I diarrhea. One case of gut grade III acute graft--host disease occurred after fecal microbiota transplantation. In patients carrying or infected by multidrug-resistant bacteria, fecal microbiota transplantation is an effective and safe decolonization strategy, even in those with hematologic malignancies undergoing hematopoietic stem cell transplantation.
粪便微生物群移植是复发性感染的有效治疗方法。 该程序还报道了根除多药耐药菌的有希望的结果,但在免疫功能低下的患者中存在安全隐患。 我们报告了 10 例接受同种异体造血干细胞移植治疗血液系统恶性肿瘤前(n=4)或后(n=6)接受多药耐药菌定植的成年患者的结果。 粪便材料来自健康的相关或无关供体。 粪便通过灌肠或鼻胃管给药。 患者定植或感染了产碳青霉烯酶细菌(n=8)或耐万古霉素肠球菌(n=2)。 粪便微生物群移植时的中位年龄为 48 岁(范围 16-64 岁)。 由于该程序最初失败,三名患者需要从同一供体进行第二次移植。 在中位随访 13 个月(范围 4-40 个月)后,十名患者中有七名实现了定植清除。 在所有患者中,粪便微生物群移植是安全的:一名患者在 FMT 后前 5 天出现便秘,两名患者出现 I 级腹泻。 粪便微生物群移植后发生 1 例肠道 III 级急性移植物抗宿主病。 在携带或感染多药耐药菌的患者中,粪便微生物群移植是一种有效且安全的定植清除策略,即使在接受造血干细胞移植的血液系统恶性肿瘤患者中也是如此。